Coverage
Filings
Danish biosolutions company Novonesis on Thursday raised its full-year sales forecast after reporting strong growth for the first nine months of the year, citing a robust performance across its markets.
Novonesis on Wednesday laid out new long-term financial targets, aiming to accelerate sales growth and expand profit margins through 2030 as part of its new ‘GROW’ strategy.
Novonesis has successfully completed its acquisition of dsm-firmenich's share of the Feed Enzyme Alliance, the company announced.
| 16 Mar 2022 |
| Transactions under Novozymes’ stock buyback program | 14 Mar 2022 |
| Transactions under Novozymes’ stock buyback program | 7 Mar 2022 |
| Transactions under Novozymes’ stock buyback program | 28 Feb 2022 |
| Initiation of stock buyback program | 21 Feb 2022 |